ACTG 254--MICRONIZED ATOVAQUONE & AZITHROMYCIN VS TRIMETHOPRIM/SULFAMETHAXZOLE

ACTG 254--微粉化阿托伐醌

• 批准号: 6246244
• 负责人: HENRY S SACKS
• 金额: $ 4.47万
• 依托单位: MOUNT SINAI SCHOOL OF MEDICINE OF CUNY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-12 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246244
• 关键词: atovaquone; azithromycin; bacterial disease; chemoprevention; clinical research; combination chemotherapy; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; pharmacokinetics; sulfamethoxazole; trimethoprim

The study seeks to determine the comparability of azithromycin plus atovaquone to TMP/SMX in prevention of serious bacterial infections. It will also determine and compare the long-term safety and tolerance (as defined by the rate of treatment-limiting adverse events) of micronized atovaquone plus azithromycin versus TMP/SMX. For the first 30 patients, the study will examine if there is a likelihood of pharmacokinetic interaction between atovaquone and azithromycin.

这项研究旨在确定阿奇霉素加阿奇霉素的可比性 阿托瓦酮与TMP/SMX联用预防严重细菌感染它 还将确定和比较长期安全性和耐受性(AS 由微粉化的治疗率-限制不良事件)定义 阿托瓦酮联合阿奇霉素与TMP/SMX的比较对于前30名患者， 这项研究将检查是否存在药代动力学的可能性 阿托瓦酮与阿奇霉素的相互作用。